Mice were injected intravenously (IV) with different LADD strains (1X10 6 CFU) or Hanks' balanced salt solution (HBSS) as a negative control.
Ad-AH1 was constructed, produced by Viraquest Inc., and IV injected into mice at a dose of 1×10 7 CFU. E7 SLP (100 µg; GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR) was formulated with AddaVax TM (InvivoGen) for subcutaneous injection following the manufacturer's instructions.
Cells, antibodies and reagents
CT26 and 4T1 cell lines were originally purchased from ATCC, the TC1 cell line was obtained from Young Kim (Johns Hopkins University) and the MC38 cell line was from Charles Drake (University of Columbia). Cell culture was performed at 37°C in a humidified atmosphere containing 5% CO2. CT26, 4T1, TC1 and MC38 were cultured in RPMI 1640 medium containing Tetramer-SPSYVYHQF and PE-H-2D b Adpgk neoepitope tetramer-ASMTNMELM were from MBL International. Gp70 antibody (rat monoclonal) was a kind gift from Jill Slansky (University of Colorado). CD8 (2.43), CD4 (GK1.5), NK1.1 (PK136), CD115 (AFS98), CCL2 (polyclonal) and PD-1 antibody (RMP1-14) for in vivo experiments were purchased from BioXCell. AH1
peptide (SPSYVYHQF), E7 peptide (RAHYNIVTF), Adpgk neoepitope peptide (ASMTNMELM), Adpgk native peptide (ASMTNTELM) and CT26 neoepitopes (6) flanks several weeks after the injection of the primary tumor. Naïve mice were used as controls.
Fresh tumor tissues were excised from mice and dissociated using a gentleMACS Dissociator (Miltenyi Biotec). Dissociated tumor samples were further digested in RPMI containing 200 µg/ml Collagenase IV (Roche) and 20 µg/ml DNase I (Sigma-Aldrich) at 37°C for 30 min. After filtering through a 40 µm nylon mesh filter, single cell suspensions were used for experiments. Total RNA was isolated using Trizol LS (Invitrogen) according to the manufacturer's instructions.
Antibody staining and flow cytometry analysis
Glycogen was used as a carrier during RNA preparation. RNA samples were sent to LC Science (Houston, TX) for sample QC, library preparation, and high-throughput sequencing (Illumina Hi-Seq 2000). The quality of fastq files was verified using FASTQC. Low quality reads were removed using FASTX-Toolkit, and reads were mapped to the mouse GRCm38/mm10 genome assembly using CLC Genomics Workbench 9, allowing for a maximum of two mismatches. Greater than 90% of reads in each sample were successfully mapped. Because RNA was pooled from multiple mice for each sample, differential gene expression was determined using a Poisson distribution using the DEGseq package. A subset of highly differentially expressed genes was validated using orthogonal methods. The raw sequence data 
LADD biodistribution studies
Briefly, CT26 tumor-bearing BALB/c mice were IV injected with LADD-AH1 at 1X10 6 CFU. The level of infection in each mouse was determined at the indicated time after LADD-AH1
challenge by enumerating bacteria in liver, spleen and tumor organ homogenates. Organs were homogenated in 5 ml 0.2% NP-40 using a gentleMACS Dissociator (Miltenyi Biotec) and dilutions of homogenates were plated onto Brain Heart Infusion agar with streptomycin (TEKNOVA). Plates were incubated at 37 o C overnight. Colonies were screened and counted by aColyte. HD (SYNBIOSIS).
Statistics
Statistical comparisons were performed with Prism software (GraphPad Software). P-values were determined as follows: differences between groups were considered significant for Pvalues *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. iNOS production by TAMs in TME. All panels were analyzed by one-way ANOVA with Tukey's multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Results are representative of at least two independent experiments.
Figure S7
Model of LADD-Ag action: Tumor-specific T cells rapidly become dysfunctional under immunosuppressive tumor microenvironment (TME) and fail to reject tumor (scenario 1). LADD-Ag promotes tumor rejection by induction of potent tumor-specific CD8 + effector T cells. These IFN-g producing CD8 + T cells infiltrate the tumor and remodel TME including a decrease in Treg level, proinflammatory cytokine mileu and the shift M2 macrophage to an iNOS + CD206 -M1 phenotype (scenario 2). Percentage of AH1 + CD8 + T cells in tumor-infiltrating CD8 + T cells. In scatter plots, each circle represents one mouse. All panels were analyzed by Mann-Whitney tests. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Results are representative of at least two independent experiments. Table S1 : RNA-seq analysis of peripheral CD8 + T cells from HBSS, LADD-AH, LADD treated CT26-tumor bearing mice (a pool of 8 mice per group). Gene expression values (TPM: transcripts per million) of selected genes out of core signature and statistics (*P < 0.05, ns: not significant) are listed in the tables. KLRG1, CX3CR1, and IFNg were confirmed by flow cytometry (Fig. 2D; S2C, E 
